-
Something wrong with this record ?
Detailed study of imatinib metabolization using high-resolution mass spectrometry
D. Friedecký, K. Mičová, E. Faber, M. Hrdá, J. Široká, T. Adam,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12218
MZ0
CEP Register
- MeSH
- Chromatography, Liquid methods MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive blood drug therapy MeSH
- Mass Spectrometry methods MeSH
- Imatinib Mesylate blood therapeutic use MeSH
- Humans MeSH
- Molecular Weight MeSH
- Antineoplastic Agents blood therapeutic use MeSH
- Software MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Modern high resolution mass spectrometry offers unique identification capability in drug metabolism studies. In this work detailed imatinib metabolization in the plasma of patients with chronic myeloid leukemia is presented. The metabolites were separated by liquid chromatography on a C18 column with mass spectrometry detection via an Orbitrap Elite instrument (Thermo Scientific) based on exact mass measurement. A scan range of m/z 350-1200 resolution of 60,000 was applied (mass accuracy of 5ppm). The data were evaluated using the advanced software for mass spectrometry Mass Frontier and MetWorks. In all plasma samples, studied 90 metabolites in the concentration range of 0.0001-1μmol/L were identified by m/z values and confirmed by exact mass measurement of the MS(2) and MS(3) fragmentations. In order to achieve optimal clinical response and avoid toxicity, current therapeutic monitoring of parent drug is a useful tool for the individualization of treatment. Current high-resolution mass spectrometry possesses the potential to broaden this approach by monitoring number of potentially clinically relevant drug metabolites.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000075
- 003
- CZ-PrNML
- 005
- 20200121083636.0
- 007
- ta
- 008
- 160108s2015 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.chroma.2015.07.033 $2 doi
- 035 __
- $a (PubMed)26199102
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Friedecký, David $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic; Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Czech Republic. Electronic address: david.friedecky@gmail.com. $7 xx0142900
- 245 10
- $a Detailed study of imatinib metabolization using high-resolution mass spectrometry / $c D. Friedecký, K. Mičová, E. Faber, M. Hrdá, J. Široká, T. Adam,
- 520 9_
- $a Modern high resolution mass spectrometry offers unique identification capability in drug metabolism studies. In this work detailed imatinib metabolization in the plasma of patients with chronic myeloid leukemia is presented. The metabolites were separated by liquid chromatography on a C18 column with mass spectrometry detection via an Orbitrap Elite instrument (Thermo Scientific) based on exact mass measurement. A scan range of m/z 350-1200 resolution of 60,000 was applied (mass accuracy of 5ppm). The data were evaluated using the advanced software for mass spectrometry Mass Frontier and MetWorks. In all plasma samples, studied 90 metabolites in the concentration range of 0.0001-1μmol/L were identified by m/z values and confirmed by exact mass measurement of the MS(2) and MS(3) fragmentations. In order to achieve optimal clinical response and avoid toxicity, current therapeutic monitoring of parent drug is a useful tool for the individualization of treatment. Current high-resolution mass spectrometry possesses the potential to broaden this approach by monitoring number of potentially clinically relevant drug metabolites.
- 650 _2
- $a protinádorové látky $x krev $x terapeutické užití $7 D000970
- 650 _2
- $a chromatografie kapalinová $x metody $7 D002853
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x krev $x terapeutické užití $7 D000068877
- 650 _2
- $a chronická myeloidní leukemie $x krev $x farmakoterapie $7 D015464
- 650 _2
- $a hmotnostní spektrometrie $x metody $7 D013058
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a software $7 D012984
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mičová, Kateřina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic; Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Czech Republic. $7 xx0260706
- 700 1_
- $a Faber, Edgar, $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Czech Republic. $d 1956- $7 xx0062699
- 700 1_
- $a Hrdá, Marcela $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic.
- 700 1_
- $a Široká, Jitka $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic.
- 700 1_
- $a Adam, Tomáš, $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Czech Republic; Laboratory for Inherited Metabolic Disorders, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Czech Republic; Department of Clinical Chemistry, University Hospital Olomouc, Czech Republic. $d 1965- $7 xx0054162
- 773 0_
- $w MED00004962 $t Journal of chromatography. A $x 1873-3778 $g Roč. 1409, č. - (2015), s. 173-81
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26199102 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20200121084013 $b ABA008
- 999 __
- $a ok $b bmc $g 1102356 $s 924281
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 1409 $c - $d 173-81 $e 20150713 $i 1873-3778 $m Journal of chromatography. A, Including electrophoresis and other separation methods $n J Chromatogr A $x MED00004962
- GRA __
- $a NT12218 $p MZ0
- LZP __
- $a Pubmed-20160108